Search

Your search keyword '"McQuilten, Zoe K."' showing total 405 results
Start Over Author "McQuilten, Zoe K."
405 results on '"McQuilten, Zoe K."'

1. The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR)

Author

Aoki, Naomi, Chen, Pin-Yen, Chen, Wenming, Chng, Wee Joo, Gan, Gin Gin, Goh, Yeow Tee, Hou, Jian, Huang, Jeffrey, Kim, Kihyun, Lee, Je Jung, Lu, Jin, McQuilten, Zoe K., Min, Chang Ki, Moore, Elizabeth, Oliver, Laura, Waters, Neil A., Wellard, Cameron, Wood, Erica M., Yeh, Su-Peng, and Spencer, Andrew

Published
2024
Full Text
View/download PDF

7. Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies

Author

Carrillo de Albornoz, Sara, Higgins, Alisa M., Petrie, Dennis, Irving, Adam, Fanning, Laura, Weinkove, Robert, Crispin, Philip, Dendle, Claire, Gilbertson, Michael, Johnston, Anna, Keegan, Anastazia, Pepperell, Dominic, Pullon, Humphrey, Reynolds, John, van Tonder, Tina, Trotman, Judith, Waters, Neil, Wellard, Cameron, Weston, Helen, Morrissey, C. Orla, Wood, Erica M., and McQuilten, Zoe K.

Published
2024
Full Text
View/download PDF

8. Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy

Author

McQuilten, Zoe K., Weinkove, Robert, Thao, Le Thi Phuong, Crispin, Philip, Degelia, Amber, Dendle, Claire, Gilbertson, Michael, Johnston, Anna, Keegan, Anastazia, Pepperell, Dominic, Pullon, Humphrey, Reynolds, John, van Tonder, Tina, Trotman, Judith, Waters, Neil, Wellard, Cameron, Weston, Helen, Morrissey, C. Orla, and Wood, Erica M.

Published
2024
Full Text
View/download PDF

9. Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19

Author

Godoy, Lucas C., Neal, Matthew D., Goligher, Ewan C., Cushman, Mary, Houston, Brett L., Bradbury, Charlotte A., McQuilten, Zoe K., Tritschler, Tobias, Kahn, Susan R., Berry, Lindsay R., Lorenzi, Elizabeth, Jensen, Tom, Higgins, Alisa M., Kornblith, Lucy Z., Berger, Jeffrey S., Gong, Michelle N., Paul, Jonathan D., Castellucci, Lana A., Le Gal, Grégoire, Lother, Sylvain A., Rosenson, Robert S., Derde, Lennie P.G., Kumar, Anand, McVerry, Bryan J., Nicolau, Jose C., Leifer, Eric, Escobedo, Jorge, Huang, David T., Reynolds, Harmony R., Carrier, Marc, Kim, Keri S., Hunt, Beverley J., Slutsky, Arthur S., Turgeon, Alexis F., Webb, Steven A., McArthur, Colin J., Farkouh, Michael E., Hochman, Judith S., Zarychanski, Ryan, and Lawler, Patrick R.

Published
2024
Full Text
View/download PDF

13. The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry

Author

Fox, Lucy C., McQuilten, Zoe K., Firkin, Frank, Fox, Vanessa, Badoux, Xavier, Bajel, Ashish, Barbaro, Pasquale, Cole-Sinclair, Merrole F., Forsyth, Cecily, Gibson, John, Hiwase, Devendra K., Johnston, Anna, Mills, Anthony, Roncolato, Fernando, Sutherland, Robyn, Szer, Jeff, Ting, Stephen B., Vilcassim, Shahla, Young, Lauren, Waters, Neil A., and Wood, Erica M.

Published
2023
Full Text
View/download PDF

17. Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study

Author

de Vos, Thijs W, Winkelhorst, Dian, Árnadóttir, Valgerdur, van der Bom, Johanna G, Canals Surís, Carme, Caram-Deelder, Camila, Deschmann, Emöke, Haysom, Helen E, Hverven, Hem Birgit C, Lozar Krivec, Jana, McQuilten, Zoe K, Muñiz-Diaz, Eduardo, Nogués, Núria, Oepkes, Dick, Porcelijn, Leendert, van der Schoot, C Ellen, Saxonhouse, Matthew, Sola-Visner, Martha, Tiblad, Eleonor, Tiller, Heidi, Wood, Erica M, Young, Vanessa, Železnik, Mojca, de Haas, Masja, and Lopriore, Enrico

Published
2022
Full Text
View/download PDF

20. The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).

Author

Ho, P. Joy, Moore, Elizabeth, Wellard, Cameron, Quach, Hang, Blacklock, Hilary, Harrrison, Simon J., MacDonald, Emma‐Jane, McQuilten, Zoe K., Wood, Erica M., Mollee, Peter, and Spencer, Andrew

Subjects
PLASMA cells, TREATMENT effectiveness, MEDICAL registries, OVERALL survival, SURVIVAL rate
Abstract

Summary: A decade after International Myeloma Working Group (IMWG) biomarkers (SLiM criteria) were introduced, this real‐world study examined their impact on diagnosis, therapy and outcomes in myeloma. Using the ANZ MRDR, 3489 newly diagnosed patients from 2013 to 2023, comprising 3232 diagnosed by CRAB ('CRAB patients', including 1758 who also satisfied ≥1 SLiM criteria) and 257 by SLiM ('SLiM patients') criteria were analysed. CRAB patients had higher R‐ISS and lower performance status, with no difference in cytogenetic risk. SLiM patients had improved progression‐free survival (PFS, 37.5 vs. 32.2 months, hazard ratio [HR] 1.31 [1.08–1.59], p = 0.003), overall survival (80.9 vs. 73.2 months, HR 1.64 [1.26–2.13], p < 0.001) and PFS2 (54.6 vs. 40.3 months, HR 1.51 [1.22–1.86], p < 0.001) compared with CRAB patients, partially explained by earlier diagnosis, with no differential impact between the plasma cell and light‐chain criteria on PFS. However, 34% of CRAB patients did not manifest SLiM characteristics, raising the possibility that SLiM features are associated with different biological behaviours contributing to a better prognosis, for example, improved PFS2 in SLiM patients suggested less disease resistance at first relapse. These data support earlier initiation of therapy by SLiM. The superior survival outcomes of SLiM versus CRAB patients highlight the importance of defining these subgroups when interpreting therapeutic outcomes at induction and first relapse. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage

Author

Caram-Deelder, Camila, primary, McKinnon Edwards, Hellen, additional, Zdanowicz, Jarmila A., additional, van den Akker, Thomas, additional, Birkegård, Camilla, additional, Blatný, Jan, additional, van der Bom, Johanna G., additional, Colucci, Giuseppe, additional, van Duuren, Derek, additional, van Geloven, Nan, additional, Henriquez, Dacia D. C. A., additional, Knight, Marian, additional, Korsholm, Lars, additional, Landorph, Andrea, additional, Lavigne Lissalde, Géraldine, additional, McQuilten, Zoe K., additional, Surbek, Daniel, additional, Wellard, Cameron, additional, Wood, Erica M., additional, and Mercier, Frederic J., additional

Published
2024
Full Text
View/download PDF

24. Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19

Author

Medische Staf Intensive Care, Infection & Immunity, Godoy, Lucas C., Neal, Matthew D., Goligher, Ewan C., Cushman, Mary, Houston, Brett L., Bradbury, Charlotte A., McQuilten, Zoe K., Tritschler, Tobias, Kahn, Susan R., Berry, Lindsay R., Lorenzi, Elizabeth, Jensen, Tom, Higgins, Alisa M., Kornblith, Lucy Z., Berger, Jeffrey S., Gong, Michelle N., Paul, Jonathan D., Castellucci, Lana A., Le Gal, Grégoire, Lother, Sylvain A., Rosenson, Robert S., Derde, Lennie P.G., Kumar, Anand, McVerry, Bryan J., Nicolau, Jose C., Leifer, Eric, Escobedo, Jorge, Huang, David T., Reynolds, Harmony R., Carrier, Marc, Kim, Keri S., Hunt, Beverley J., Slutsky, Arthur S., Turgeon, Alexis F., Webb, Steven A., McArthur, Colin J., Farkouh, Michael E., Hochman, Judith S., Zarychanski, Ryan, Lawler, Patrick R., Medische Staf Intensive Care, Infection & Immunity, Godoy, Lucas C., Neal, Matthew D., Goligher, Ewan C., Cushman, Mary, Houston, Brett L., Bradbury, Charlotte A., McQuilten, Zoe K., Tritschler, Tobias, Kahn, Susan R., Berry, Lindsay R., Lorenzi, Elizabeth, Jensen, Tom, Higgins, Alisa M., Kornblith, Lucy Z., Berger, Jeffrey S., Gong, Michelle N., Paul, Jonathan D., Castellucci, Lana A., Le Gal, Grégoire, Lother, Sylvain A., Rosenson, Robert S., Derde, Lennie P.G., Kumar, Anand, McVerry, Bryan J., Nicolau, Jose C., Leifer, Eric, Escobedo, Jorge, Huang, David T., Reynolds, Harmony R., Carrier, Marc, Kim, Keri S., Hunt, Beverley J., Slutsky, Arthur S., Turgeon, Alexis F., Webb, Steven A., McArthur, Colin J., Farkouh, Michael E., Hochman, Judith S., Zarychanski, Ryan, and Lawler, Patrick R.

Published
2024

25. Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.

Author

Irving, Adam, Petrie, Dennis, Harris, Anthony, Fanning, Laura, Wood, Erica M., Moore, Elizabeth, Wellard, Cameron, Waters, Neil, Huynh, Kim, Augustson, Bradley, Cook, Gordon, Gay, Francesca, McCaughan, Georgia, Mollee, Peter, Spencer, Andrew, and McQuilten, Zoe K.

Subjects
PLASMA cells, MULTIPLE myeloma, STEM cell transplantation, THERAPEUTICS, BONE marrow cells, SURVIVAL analysis (Biometry)
Abstract

Multiple myeloma is a haematological malignancy typically characterised by neoplastic plasma cell infiltration of the bone marrow. Treatment for multiple myeloma consists of multi-line chemotherapy with or without autologous stem cell transplantation and has been rapidly evolving in recent years. However, clinical trials are unable to provide patients and clinicians with long-term prognostic information nor policymakers with the full body of evidence needed to perform economic evaluation of new therapies or make reimbursement decisions. To address these limitations of the available evidence, this study aimed to develop and validate the EpiMAP Myeloma model, a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways. Risk equations were estimated using the Australian and New Zealand Myeloma & Related Diseases Registry after multiple imputation of missing data. Risk equation coefficients were combined with multiple myeloma patients at diagnosis from the Registry to perform the simulation. The model was validated with 100 bootstraps of an out-of-sample prediction analysis using a 70/30 split of the 4,121 registry patients diagnosed between 2009 and 2023, resulting in 2,884 and 1,237 patients in the training and validation cohorts, respectively. For 90% of the 120 months in the 10-year post-diagnosis period, there was no significant difference in overall survival between the validation and simulated cohorts. These results highlight that the EpiMAP Myeloma model is robust at predicting multiple myeloma disease outcomes and treatment pathways in Australia & New Zealand. In the future, clinicians will be able to use the EpiMAP Myeloma model to provide personalised estimates of life expectancy to patients based on their specific characteristics, disease stage, and response to treatment. Policymakers will also be able to use the model to perform economic evaluation, to forecast the number of patients receiving treatment at different stages, and to determine the downstream impact of listing new, effective therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Author

Axfors, Cathrine, Janiaud, Perrine, Schmitt, Andreas M., van’t Hooft, Janneke, Smith, Emily R., Haber, Noah A., Abayomi, Akin, Abduljalil, Manal, Abdulrahman, Abdulkarim, Acosta-Ampudia, Yeny, Aguilar-Guisado, Manuela, Al-Beidh, Farah, Alejandria, Marissa M., Alfonso, Rachelle N., Ali, Mohammad, AlQahtani, Manaf, AlZamrooni, Alaa, Anaya, Juan-Manuel, Ang, Mark Angelo C., Aomar, Ismael F., Argumanis, Luis E., Averyanov, Alexander, Baklaushev, Vladimir P., Balionis, Olga, Benfield, Thomas, Berry, Scott, Birocco, Nadia, Bonifacio, Lynn B., Bowen, Asha C., Bown, Abbie, Cabello-Gutierrez, Carlos, Camacho, Bernardo, Camacho-Ortiz, Adrian, Campbell-Lee, Sally, Cao, Damon H., Cardesa, Ana, Carnate, Jose M., Castillo, German Jr. J., Cavallo, Rossana, Chowdhury, Fazle R., Chowdhury, Forhad U. H., Ciccone, Giovannino, Cingolani, Antonella, Climacosa, Fresthel Monica M., Compernolle, Veerle, Cortez, Carlo Francisco N., Costa Neto, Abel, D’Antico, Sergio, Daly, James, Danielle, Franca, Davis, Joshua S., De Rosa, Francesco Giuseppe, Denholm, Justin T., Denkinger, Claudia M., Desmecht, Daniel, Díaz-Coronado, Juan C., Díaz Ponce-Medrano, Juan A., Donneau, Anne-Françoise, Dumagay, Teresita E., Dunachie, Susanna, Dungog, Cecile C., Erinoso, Olufemi, Escasa, Ivy Mae S., Estcourt, Lise J., Evans, Amy, Evasan, Agnes L. M., Fareli, Christian J., Fernandez-Sanchez, Veronica, Galassi, Claudia, Gallo, Juan E., Garcia, Patricia J., Garcia, Patricia L., Garcia, Jesus A., Garigliany, Mutien, Garza-Gonzalez, Elvira, Gauiran, Deonne Thaddeus V., Gaviria García, Paula A., Giron-Gonzalez, Jose-Antonio, Gómez-Almaguer, David, Gordon, Anthony C., Gothot, André, Grass Guaqueta, Jeser Santiago, Green, Cameron, Grimaldi, David, Hammond, Naomi E., Harvala, Heli, Heralde, Francisco M., Herrick, Jesica, Higgins, Alisa M., Hills, Thomas E., Hines, Jennifer, Holm, Karin, Hoque, Ashraful, Hoste, Eric, Ignacio, Jose M., Ivanov, Alexander V., Janssen, Maike, Jennings, Jeffrey H., Jha, Vivekanand, King, Ruby Anne N., Kjeldsen-Kragh, Jens, Klenerman, Paul, Kotecha, Aditya, Krapp, Fiorella, Labanca, Luciana, Laing, Emma, Landin-Olsson, Mona, Laterre, Pierre-François, Lim, Lyn-Li, Lim, Jodor, Ljungquist, Oskar, Llaca-Díaz, Jorge M., López-Robles, Concepción, López-Cárdenas, Salvador, Lopez-Plaza, Ileana, Lucero, Josephine Anne C., Lundgren, Maria, Macías, Juan, Maganito, Sandy C., Malundo, Anna Flor G., Manrique, Rubén D., Manzini, Paola M., Marcos, Miguel, Marquez, Ignacio, Martínez-Marcos, Francisco Javier, Mata, Ana M., McArthur, Colin J., McQuilten, Zoe K., McVerry, Bryan J., Menon, David K., Meyfroidt, Geert, Mirasol, Ma. Angelina L., Misset, Benoît, Molton, James S., Mondragon, Alric V., Monsalve, Diana M., Moradi Choghakabodi, Parastoo, Morpeth, Susan C., Mouncey, Paul R., Moutschen, Michel, Müller-Tidow, Carsten, Murphy, Erin, Najdovski, Tome, Nichol, Alistair D., Nielsen, Henrik, Novak, Richard M., O’Sullivan, Matthew V. N., Olalla, Julian, Osibogun, Akin, Osikomaiya, Bodunrin, Oyonarte, Salvador, Pardo-Oviedo, Juan M., Patel, Mahesh C., Paterson, David L., Peña-Perez, Carlos A., Perez-Calatayud, Angel A., Pérez-Alba, Eduardo, Perkina, Anastasia, Perry, Naomi, Pouladzadeh, Mandana, Poyato, Inmaculada, Price, David J., Quero, Anne Kristine H., Rahman, Md. M., Rahman, Md. S., Ramesh, Mayur, Ramírez-Santana, Carolina, Rasmussen, Magnus, Rees, Megan A., Rego, Eduardo, Roberts, Jason A., Roberts, David J., Rodríguez, Yhojan, Rodríguez-Baño, Jesús, Rogers, Benjamin A., Rojas, Manuel, Romero, Alberto, Rowan, Kathryn M., Saccona, Fabio, Safdarian, Mehdi, Santos, Maria Clariza M., Sasadeusz, Joe, Scozzari, Gitana, Shankar-Hari, Manu, Sharma, Gorav, Snelling, Thomas, Soto, Alonso, Tagayuna, Pedrito Y., Tang, Amy, Tatem, Geneva, Teofili, Luciana, Tong, Steven Y. C., Turgeon, Alexis F., Veloso, Januario D., Venkatesh, Balasubramanian, Ventura-Enriquez, Yanet, Webb, Steve A., Wiese, Lothar, Wikén, Christian, Wood, Erica M., Yusubalieva, Gaukhar M., Zacharowski, Kai, Zarychanski, Ryan, Khanna, Nina, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2021
Full Text
View/download PDF

28. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry

Author

Ho, P. Joy, Moore, Elizabeth M., McQuilten, Zoe K., Wellard, Cameron, Bergin, Krystal, Augustson, Bradley, Blacklock, Hilary, Harrison, Simon J., Horvath, Noemi, King, Tracy, Mollee, Peter, Quach, Hang, Reid, Christopher, Rosengarten, Brian, Walker, Patricia, Wood, Erica M., and Spencer, Andrew

Published
2019
Full Text
View/download PDF

29. Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey.

Author

Mo, Allison, Weinkove, Robert, Wood, Erica M., Shortt, Jake, Johnston, Anna, and McQuilten, Zoe K.

Subjects
BLOOD platelet transfusion, TRANEXAMIC acid, MYELODYSPLASTIC syndromes, POTENTIAL barrier, TRIAL practice, BLOOD transfusion reaction
Abstract

Aim: Thrombocytopenia and bleeding are common in myelodysplastic syndromes (MDS), but optimal management is unknown. We conducted a survey to identify current clinical practice regarding platelet transfusion (PLT‐T) and tranexamic acid (TXA) to inform future trial design. Method: A 25‐question survey was distributed to members of the ALLG from December 2020 to July 2021. Results: Sixty‐four clinicians across Australia, New Zealand and Singapore responded. Clinicians treated a median of 15 MDS patients annually. Twenty‐nine (45%) reported having institutional guidelines regarding prophylactic PLT‐T. Although 60 (94%) said they would consider using TXA, most (58/64; 91%) did not have institutional guidelines. Clinical scenarios showed prophylactic PLT‐T was more likely administered for patients on disease‐modifying therapy (49/64; 76%, commonest threshold <10 × 109/L) or with minor bleeding (32/64 [50%] transfusing at threshold <20 × 109/L, 23/64 [35%] at <10 × 109/L). For stable untreated patients, 29/64 (45%) would not give PLT‐T and 32/64 (50%) would. Most respondents (46/64; 72%) were interested in participating in trials in this area. Potential barriers included resource limitations, funding and patient/clinician acceptance. Conclusion: Real‐world management of MDS‐related thrombocytopenia varies and there is a need for clinical trials to inform practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. A Randomized Trial of Nafamostat for Covid-19

Author

Morpeth, Susan C., primary, Venkatesh, Balasubramanian, additional, Totterdell, James A., additional, McPhee, Grace M., additional, Mahar, Robert K., additional, Jones, Mark, additional, Bandara, Methma, additional, Barina, Lauren A., additional, Basnet, Bhupendra K., additional, Bowen, Asha C., additional, Burke, Andrew J., additional, Cochrane, Belinda, additional, Denholm, Justin T., additional, Dhungana, Ashesh, additional, Dore, Gregory J., additional, Dotel, Ravindra, additional, Duffy, Eamon, additional, Dummer, Jack, additional, Foo, Hong, additional, Gilbey, Timothy L., additional, Hammond, Naomi E., additional, Hudson, Bernard J., additional, Jha, Vivekanand, additional, Jevaji, Purnima R., additional, John, Oommen, additional, Joshi, Rajesh, additional, Kang, Gagandeep, additional, Kaur, Baldeep, additional, Kim, Seungtaek, additional, Das, Santa Kumar, additional, Lau, Jillian S.Y., additional, Littleford, Roberta, additional, Marsh, Julie A., additional, Marschner, Ian C., additional, Matthews, Gail, additional, Maze, Michael J., additional, McArthur, Colin J., additional, McFadyen, James D., additional, McMahon, James H., additional, McQuilten, Zoe K., additional, Molton, James, additional, Mora, Jocelyn M., additional, Mudaliar, Vijaybabu, additional, Nguyen, Vi, additional, O’Sullivan, Matthew V.N., additional, Pant, Suman, additional, Park, Jaha E., additional, Paterson, David L., additional, Price, David J., additional, Raymond, Nigel, additional, Rees, Megan A., additional, Robinson, James O., additional, Rogers, Benjamin A., additional, Ryu, Wang-Shick, additional, Sasadeusz, Joe, additional, Shum, Omar, additional, Snelling, Thomas L., additional, Sommerville, Christine, additional, Trask, Nanette, additional, Lewin, Sharon R., additional, Hills, Thomas E., additional, Davis, Joshua S., additional, Roberts, Jason A., additional, and Tong, Steven Y.C., additional

Published
2023
Full Text
View/download PDF

33. Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly

Author

McQuilten, Zoe K., primary, Thao, Le Thi Phuong, additional, Pasricha, Sant-Rayn, additional, Artz, Andrew S., additional, Bailey, Michael, additional, Chan, Andrew T., additional, Cohen, Harvey Jay, additional, Lockery, Jessica E., additional, Murray, Anne M., additional, Nelson, Mark R., additional, Schneider, Hans G., additional, Wolfe, Rory, additional, Woods, Robyn L., additional, Wood, Erica M., additional, and McNeil, John J., additional

Published
2023
Full Text
View/download PDF

34. Clinician perceptions of research priorities for the management of noncritically ill patients admitted to hospital with SARS‐CoV‐2 infection.

Author

Bandara, Methma M., Barina, Lauren A., McPhee, Grace M., Goulding, Susan R., Denholm, Justin T., Morpeth, Susan C., Tong, Steven Y. C., Basnet, Bhupendra K., Bowen, Asha C., Hammond, Naomi E., Jha, Vivekanand, Jones, Mark, McQuilten, Zoe K., Mora, Jocelyn M., Nguyen, Vi, O'Sullivan, Matthew V. N., Paterson, David L., Price, David J., Rees, Megan A., and Snelling, Thomas L.

Subjects
EXPERIMENTAL design, PUBLIC health surveillance, COVID-19, RESEARCH evaluation, PRIORITY (Philosophy), ATTITUDES of medical personnel, RESEARCH methodology, IMMUNOCOMPROMISED patients, CROSS infection, DISEASE incidence, ANTIVIRAL agents, AUSTRALASIANS, SEVERITY of illness index, PATIENTS' attitudes, QUESTIONNAIRES, HEALTH attitudes, DISEASE prevalence, CRITICAL care medicine, DESCRIPTIVE statistics, RESEARCH funding, PATIENT care, CONTENT analysis, THEMATIC analysis, PHENOTYPES
Abstract

The changing phenotype of coronarvirus disease 2019 (COVID‐19) may quickly render guideline‐recommended interventions obsolete. We developed a 40‐question clinician survey in consultation with the Australasian COVID‐19 Trial site investigators. The survey was designed to assess clinician perceptions of the current treatment strategies and future research priorities in the management of non‐critically ill patients admitted to hospital with SARS‐CoV‐2 infection. There were 84 complete responses from predominantly Australian and New Zealand clinicians. The perceived prevalence of patients with incidental COVID‐19, nosocomial infection, underlying illness exacerbated by COVID‐19, and/or immunocompromised status suggests new populations to target. The results highlighted clinician interest in antiviral therapies for future research in both immunocompetent and immunocompromised cohorts. These survey results underscore the need for ongoing surveillance of COVID‐19 disease phenotypes and clinician and patient priorities for future research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Pre‐hospital freeze‐dried plasma for critical bleeding after trauma: A pilot randomized controlled trial

Author

Mitra, Biswadev, primary, Meadley, Ben, additional, Bernard, Stephen, additional, Maegele, Marc, additional, Gruen, Russell L., additional, Bradley, Olivia, additional, Wood, Erica M., additional, McQuilten, Zoe K., additional, Fitzgerald, Mark, additional, St. Clair, Toby, additional, Webb, Andrew, additional, Anderson, David, additional, and Reade, Michael C., additional

Published
2023
Full Text
View/download PDF

38. Anticoagulation Strategies in Non–Critically Ill Patients with Covid-19

Author

McQuilten, Zoe K., primary, Venkatesh, Balasubramanian, additional, Jha, Vivekanand, additional, Roberts, Jason, additional, Morpeth, Susan C., additional, Totterdell, James A., additional, McPhee, Grace M., additional, Abraham, John, additional, Bam, Niraj, additional, Bandara, Methma, additional, Bangi, Ashpak K., additional, Barina, Lauren A., additional, Basnet, Bhupendra K., additional, Bhally, Hasan, additional, Bhusal, Khema R., additional, Bogati, Umesh, additional, Bowen, Asha C., additional, Burke, Andrew J., additional, Christopher, Devasahayam J., additional, Chunilal, Sanjeev D., additional, Cochrane, Belinda, additional, Curnow, Jennifer L., additional, Das, Santa Kumar, additional, Dhungana, Ashesh, additional, Di Tanna, Gian Luca, additional, Dotel, Ravindra, additional, DSouza, Hyjel, additional, Dummer, Jack, additional, Dutta, Sourabh, additional, Foo, Hong, additional, Gilbey, Timothy L., additional, Giles, Michelle L., additional, Goli, Kasiram, additional, Gordon, Adrienne, additional, Gyanwali, Pradip, additional, Haksar, Dipak, additional, Hudson, Bernard J., additional, Jani, Manoj K., additional, Jevaji, Purnima R., additional, Jhawar, Sachin, additional, Jindal, Aikaj, additional, John, M. Joseph, additional, John, Mary, additional, John, Flavita B., additional, John, Oommen, additional, Jones, Mark, additional, Joshi, Rajesh D., additional, Kamath, Prashanthi, additional, Kang, Gagandeep, additional, Karki, Achyut R., additional, Karmalkar, Abhishek M., additional, Kaur, Baldeep, additional, Koganti, Kalyan Chakravarthy, additional, Koshy, Jency M., additional, Krishnamurthy, Mathew S., additional, Lau, Jillian S., additional, Lewin, Sharon R., additional, Lim, Lyn-li, additional, Marschner, Ian C., additional, Marsh, Julie A., additional, Maze, Michael J., additional, McGree, James M., additional, McMahon, James H., additional, Medcalf, Robert L., additional, Merriman, Eileen G., additional, Misal, Amol P., additional, Mora, Jocelyn M., additional, Mudaliar, Vijaybabu K., additional, Nguyen, Vi, additional, O’Sullivan, Matthew V., additional, Pant, Suman, additional, Pant, Pankaj, additional, Paterson, David L., additional, Price, David J., additional, Rees, Megan A., additional, Robinson, James O., additional, Rogers, Benjamin A., additional, Samuel, Sandhya, additional, Sasadeusz, Joe, additional, Sharma, Deepak, additional, Sharma, Prabhat K., additional, Shrestha, Roshan, additional, Shrestha, Sailesh K., additional, Shrestha, Prajowl, additional, Shukla, Urvi, additional, Shum, Omar, additional, Sommerville, Christine, additional, Spelman, Tim, additional, Sullivan, Richard P., additional, Thatavarthi, Umashankar, additional, Tran, Huyen A., additional, Trask, Nanette, additional, Whitehead, Clare L., additional, Mahar, Robert K., additional, Hammond, Naomi E., additional, McFadyen, James D., additional, Snelling, Thomas L., additional, Davis, Joshua S., additional, Denholm, Justin T., additional, and Tong, Steven Y.C., additional

Published
2023
Full Text
View/download PDF

41. Monoclonal antibody levels and protection from COVID-19

Author

Stadler, Eva, primary, Burgess, Martin T, additional, Schlub, Timothy E, additional, Chai, Khai Li, additional, McQuilten, Zoe K, additional, Wood, Erica M, additional, Polizzotto, Mark N, additional, Kent, Stephen J, additional, Cromer, Deborah, additional, Davenport, Miles P, additional, and Khoury, David S, additional

Published
2022
Full Text
View/download PDF

48. Determinants of passive antibody efficacy in SARS-CoV-2 infection

Author

Stadler, Eva, primary, Chai, Khai Li, additional, Schlub, Timothy E, additional, Cromer, Deborah, additional, Polizzotto, Mark N, additional, Kent, Stephen J, additional, Beecher, Claire, additional, White, Heath, additional, Turner, Tari, additional, Skoetz, Nicole, additional, Estcourt, Lise, additional, McQuilten, Zoe K, additional, Wood, Erica M, additional, Khoury, David S, additional, and Davenport, Miles P, additional

Published
2022
Full Text
View/download PDF

49. Determinants of passive antibody effectiveness in SARS-CoV-2 infection

Author

Stadler, Eva, Chai, Khai Li, Schlub, Timothy E, Cromer, Deborah, Polizzotto, Mark N, Kent, Stephen J, Skoetz, Nicole, Estcourt, Lise, McQuilten, Zoe K, Wood, Erica M, Khoury, David S, and Davenport, Miles P

Subjects
Coronavirus, COVID-19
Abstract

Neutralising antibodies are an important correlate of protection from SARS-CoV-2 infection. Multiple studies have investigated the effectiveness of passively administered antibodies (either monoclonal antibodies, convalescent plasma or hyperimmune immunoglobulin) in preventing acquisition of or improving the outcome of infection. Comparing the results between studies is challenging due to different study characteristics including disease stage, trial enrolment and outcome criteria, and different product factors, including administration of polyclonal or monoclonal antibody, and antibody targets and doses. Here we integrate data from 37 randomised controlled trials to investigate how the timing and dose of passive antibodies predicts protection from SARS-CoV-2 infection. We find that both prophylactic and early therapeutic administration (to symptomatic ambulant subjects) have significant efficacy in preventing infection or progression to hospitalisation respectively. However, we find that effectiveness of passive antibody therapy in preventing clinical progression is significantly reduced with administration at later clinical stages (p1000-fold lower than currently used could still achieve around 90% of the current effectiveness (depending on the variant) and allow much more widespread use at lower cost. For convalescent plasma, most current doses are lower than required for high levels of protection. This work provides a framework for the rational design of future passive antibody prophylaxis and treatment strategies for COVID-19.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results